Renaissance Technologies LLC Buys 162,100 Shares of Protalix BioTherapeutics, Inc. (NYSE:PLX)

Renaissance Technologies LLC grew its stake in shares of Protalix BioTherapeutics, Inc. (NYSE:PLX) by 17.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,118,000 shares of the company’s stock after purchasing an additional 162,100 shares during the period. Renaissance Technologies LLC owned approximately 1.52% of Protalix BioTherapeutics worth $2,102,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Y Intercept Hong Kong Ltd bought a new stake in Protalix BioTherapeutics during the 4th quarter valued at approximately $35,000. Sanctuary Advisors LLC purchased a new stake in Protalix BioTherapeutics in the third quarter worth $38,000. PFG Investments LLC bought a new position in Protalix BioTherapeutics in the fourth quarter worth $39,000. Virtu Financial LLC purchased a new position in Protalix BioTherapeutics during the third quarter valued at $44,000. Finally, Prudential Financial Inc. bought a new stake in shares of Protalix BioTherapeutics during the 4th quarter valued at $68,000. Hedge funds and other institutional investors own 16.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PLX. StockNews.com lowered shares of Protalix BioTherapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, March 20th. HC Wainwright raised their target price on shares of Protalix BioTherapeutics from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, February 3rd.

Protalix BioTherapeutics Trading Down 3.1 %

NYSE PLX opened at $2.85 on Friday. Protalix BioTherapeutics, Inc. has a 12 month low of $0.82 and a 12 month high of $3.04. The stock’s fifty day moving average price is $2.45 and its 200-day moving average price is $2.02. The stock has a market cap of $222.39 million, a P/E ratio of -21.92 and a beta of 0.46.

Protalix BioTherapeutics Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.